吉西他滨联合大剂量顺铂治疗晚期非小细胞肺癌

目的观察吉西他滨(Gemcitabine GEM)联合大剂量顺铂(HD—DDP)方案治疗晚期非小细胞肺癌(ANSCLC)的近期疗效及其不良反应。方法经病理组织学或细胞学证实的26例晚期非小细胞肺癌用吉西他滨1000mg／m^2。静脉滴注，第1，8，15天，顺铂80～100mg/m^2静脉滴注，第1天，4周为1周期。所有病人至少接受2周期治疗。结果可评价疗效26例，总有效率46．2％，初治病例14例，有效率57．1％。复治病例12例，有效率33．3％。主要毒副作用是骨髓抑制，恶心呕吐，其他毒性反应均轻微可耐受。结论吉西他滨联合大剂量顺铂治疗晚期非小细胞肺癌具有较好疗效，毒性可耐受，是治疗晚期非小细胞肺癌较理想方案之

Clinical observation of combined chemotherapy of gemcitabine and HD - DDP for advanced non - small - cell Lung cancer

Objective To evaluate the efficacy and to xi city of Gemcitabine and HD-DDP for advanced non-small-cell lung cancer. Methods Twenty six patients with ANSCLC diagnosed by pathology or cytology were enrolled in the study.The patients received Gemcitabine 1000mg/ m 2 on d1,8,15 and HD-DDP 80-100mg/ m2 on d1 of 4 weeks regimen. All patients received at least two cycles of the treatment. Results Tw enty six of all the cases could be evaluated.The total response rate (RR) was 4 6.2%,The RR of 14 the first treatment patients was 57.1%.The RR of 12 recurrent patients were 33.3%.The major side effects were neutropenia,nausea vomiting,the other toxicity were mild and tolerable. Conclusion The c ombination of Gemcitabine and HD-DDP is an effective and tolerable regimen in th e treatment of ANSCLC.It could be considered as one of the standard therapies.